American Society of Hirudotherapy

Bleeding Associated With Antiarrhythmic Drugs in Patients With Atrial Fibrillation Using Direct Oral Anticoagulants: A Nationwide Population Cohort Study

Nationwide population-based retrospective cohort study published in Journal of the American Heart Association (2024)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Research reportClinical LiteratureWu et al. · Journal of the American Heart Association, 2024

Abstract

BACKGROUND: This study investigated drug-drug interactions in patients with atrial fibrillation taking both a direct oral anticoagulant (DOAC) and an antiarrhythmic drug. METHODS AND RESULTS: Using data from the National Health Insurance database (2012-2018), we identified 78 805 patients with atrial fibrillation on DOACs, with 24 142 taking amiodarone, 8631 taking propafenone, 2784 taking dronedarone, 297 taking flecainide, 177 taking sotalol, and 42 772 on DOACs alone. Patients with bradycardia, heart block, heart failure, mitral stenosis, prosthetic valves, or incomplete data were excluded. Propensity score matching compared those taking both DOACs and antiarrhythmic drugs with those on DOACs alone. There was an increased risk of major bleeding in patients concomitantly taking DOACs with amiodarone when compared with matched patients taking DOACs alone (hazard ratio [HR],1.13 [95% CI, 1.04-1.23]; P=0.0044), particularly in patients taking dabigatran (HR, 1.19 [95% CI, 1.03-1.38]; P=0.0175). No significant difference in bleeding risk was found for propafenone, dronedarone, flecainide, or sotalol. The small sample sizes in the flecainide and sotalol groups limit interpretation. Notably, intracranial bleeding risk was higher in patients on DOACs and amiodarone, regardless of age. Additionally, patients <80 years old taking dabigatran with amiodarone or propafenone had a higher risk of gastrointestinal bleeding. CONCLUSIONS: Concomitant use of DOACs with amiodarone, but not dronedarone or propafenone, increases the risk of major bleeding, particularly intracranial bleeding. This study provides new evidence to guide clinicians to tailor concomitant anticoagulation and antiarrhythmic therapy for patients with atrial fibrillation.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsHumansAtrial FibrillationAnti-Arrhythmia AgentsMaleFemaleAgedHemorrhageAdministration, OralMiddle AgedDrug InteractionsAged, 80 and overAmiodaroneFactor Xa InhibitorsTaiwanRisk FactorsDatabases, FactualRetrospective StudiesRisk AssessmentAnticoagulantsDronedaroneDabigatranSotalolDrug Therapy, Combination

Summary

In a national health insurance cohort of 78,805 atrial fibrillation patients on DOACs, concomitant amiodarone (especially with dabigatran) was associated with increased major and intracranial bleeding, while propafenone, dronedarone, flecainide, and sotalol showed no significant excess risk.

Why This Matters for Hirudotherapy

This nationwide population cohort (78,805 atrial fibrillation patients on DOACs, 2012-2018) investigated drug-drug interactions with antiarrhythmics and found that concomitant amiodarone — but not dronedarone or propafenone — increased major bleeding risk versus DOAC alone (HR 1.13), with the signal especially marked for intracranial bleeding and for dabigatran (HR 1.19), while flecainide and sotalol groups were too small to interpret. The hirudotherapy connection is indirect: dabigatran is a direct thrombin inhibitor sharing hirudin's enzymatic target, so the bleeding-interaction data inform the safety landscape of the thrombin-inhibition class that the leech secretome story draws on. Caveat: this is an observational cohort of synthetic oral anticoagulants and antiarrhythmics — it does not study leech therapy, the associations are not causal, and the small flecainide/sotalol samples limit those subgroups.

Citation

Reference (Vancouver style)

Wu VC, Wang CL, Huang YC, Tu HT, Huang YT, Kuo CF, et al. Bleeding Associated With Antiarrhythmic Drugs in Patients With Atrial Fibrillation Using Direct Oral Anticoagulants: A Nationwide Population Cohort Study. J Am Heart Assoc. 2024;13(21):e033513. doi:10.1161/JAHA.123.033513. PMID: 39494558

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 29, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.